Literature DB >> 34933798

Lung transplantation for idiopathic pulmonary fibrosis enriches for individuals with telomere-mediated disease.

Jonathan K Alder1, Rachel M Sutton2, Carlo J Iasella3, Mehdi Nouraie2, Ritchie Koshy4, Stefanie J Hannan4, Ernest G Chan5, Xiaoping Chen4, Yingze Zhang6, Mark Brown4, Iulia Popescu4, Melinda Veatch2, Melissa Saul4, Annerose Berndt4, Barbara A Methé4, Alison Morris4, Joseph M Pilewski4, Pablo G Sanchez5, Matthew R Morrell4, Steven D Shapiro4, Kathleen O Lindell7, Kevin F Gibson2, Daniel J Kass2, John F McDyer8.   

Abstract

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is the most common indication for lung transplantation in North America and variants in telomere-maintenance genes are the most common identifiable cause of IPF. We reasoned that younger IPF patients are more likely to undergo lung transplantation and we hypothesized that lung transplant recipients would be enriched for individuals with telomere-mediated disease due to the earlier onset and more severe disease in these patients.
METHODS: Individuals with IPF who underwent lung transplantation or were evaluated in an interstitial lung disease specialty clinic who did not undergo lung transplantation were examined. Genetic evaluation was completed via whole genome sequencing (WGS) of 426 individuals and targeted sequencing for 5 individuals. Rare variants in genes previously associated with IPF were classified using the American College of Medical Genetics guidelines. Telomere length from WGS data was measured using TelSeq software. Patient characteristics were collected via medical record review.
RESULTS: Of 431 individuals, 149 underwent lung transplantation for IPF. The median age of diagnosis of transplanted vs non-transplanted individuals was significantly younger (60 years vs 70 years, respectively, p<0.0001). IPF lung transplant recipients (IPF-LTRs) were twice as likely to have telomere-related rare variants compared to non-transplanted individuals (24% vs 12%, respectively, p=0.0013). IPF-LTRs had shorter telomeres than non-transplanted IPF patients (p=0.0028) and >85% had telomeres below the age-adjusted mean. Post-transplant survival and CLAD were similar amongst IPF-LTRs with rare variants in telomere-maintenance genes compared to those without, as well as in those with short telomeres versus longer telomeres.
CONCLUSIONS: There is an enrichment for telomere-maintenance gene variants and short telomeres among IPF-LTRs. However, transplant outcomes of survival and CLAD do not differ by gene variants or telomere length within IPF-LTRs. Our findings support individual with telomere-mediated disease should not be excluded from lung transplantation and focusing research efforts on therapies directed toward individuals with short-telomere mediated disease.
Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  CLAD; IPF; genetic testing; telomerase; telomere length; transplant

Mesh:

Year:  2021        PMID: 34933798      PMCID: PMC9038609          DOI: 10.1016/j.healun.2021.11.008

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   13.569


  45 in total

1.  The Registry of the International Society for Heart and Lung Transplantation: Twenty-sixth Official Adult Lung and Heart-Lung Transplantation Report-2009.

Authors:  Jason D Christie; Leah B Edwards; Paul Aurora; Fabienne Dobbels; Richard Kirk; Axel O Rahmel; Josef Stehlik; David O Taylor; Anna Y Kucheryavaya; Marshall I Hertz
Journal:  J Heart Lung Transplant       Date:  2009-10       Impact factor: 10.247

2.  An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.

Authors:  Ganesh Raghu; Harold R Collard; Jim J Egan; Fernando J Martinez; Juergen Behr; Kevin K Brown; Thomas V Colby; Jean-François Cordier; Kevin R Flaherty; Joseph A Lasky; David A Lynch; Jay H Ryu; Jeffrey J Swigris; Athol U Wells; Julio Ancochea; Demosthenes Bouros; Carlos Carvalho; Ulrich Costabel; Masahito Ebina; David M Hansell; Takeshi Johkoh; Dong Soon Kim; Talmadge E King; Yasuhiro Kondoh; Jeffrey Myers; Nestor L Müller; Andrew G Nicholson; Luca Richeldi; Moisés Selman; Rosalind F Dudden; Barbara S Griss; Shandra L Protzko; Holger J Schünemann
Journal:  Am J Respir Crit Care Med       Date:  2011-03-15       Impact factor: 21.405

3.  Lung Transplant Outcomes in Patients With Pulmonary Fibrosis With Telomere-Related Gene Variants.

Authors:  Aparna C Swaminathan; Megan L Neely; Courtney W Frankel; Fran L Kelly; Slavé Petrovski; Michael T Durheim; Erika Bush; Laurie Snyder; David B Goldstein; Jamie L Todd; Scott M Palmer
Journal:  Chest       Date:  2019-04-09       Impact factor: 9.410

4.  Interstitial Lung Disease in Relatives of Patients with Pulmonary Fibrosis.

Authors:  Gary M Hunninghake; Luisa D Quesada-Arias; Nikkola E Carmichael; Jose M Martinez Manzano; Sergio Poli De Frías; Maura Alvarez Baumgartner; Lisa DiGianni; Shannon N Gampala-Sagar; Dominick A Leone; Swati Gulati; Souheil El-Chemaly; Hilary J Goldberg; Rachel K Putman; Hiroto Hatabu; Benjamin A Raby; Ivan O Rosas
Journal:  Am J Respir Crit Care Med       Date:  2020-05-15       Impact factor: 21.405

5.  An international ISHLT/ATS/ERS clinical practice guideline: diagnosis and management of bronchiolitis obliterans syndrome.

Authors:  Keith C Meyer; Ganesh Raghu; Geert M Verleden; Paul A Corris; Paul Aurora; Kevin C Wilson; Jan Brozek; Allan R Glanville
Journal:  Eur Respir J       Date:  2014-10-30       Impact factor: 16.671

6.  Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validation.

Authors:  Bridget D Stuart; Joyce S Lee; Julia Kozlitina; Imre Noth; Megan S Devine; Craig S Glazer; Fernando Torres; Vaidehi Kaza; Carlos E Girod; Kirk D Jones; Brett M Elicker; Shwu-Fan Ma; Rekha Vij; Harold R Collard; Paul J Wolters; Christine Kim Garcia
Journal:  Lancet Respir Med       Date:  2014-06-16       Impact factor: 30.700

7.  Loss-of-function mutations in the RNA biogenesis factor NAF1 predispose to pulmonary fibrosis-emphysema.

Authors:  Susan E Stanley; Dustin L Gable; Christa L Wagner; Thomas M Carlile; Vidya Sagar Hanumanthu; Joshua D Podlevsky; Sara E Khalil; Amy E DeZern; Maria F Rojas-Duran; Carolyn D Applegate; Jonathan K Alder; Erin M Parry; Wendy V Gilbert; Mary Armanios
Journal:  Sci Transl Med       Date:  2016-08-10       Impact factor: 17.956

8.  Telomere phenotypes in females with heterozygous mutations in the dyskeratosis congenita 1 (DKC1) gene.

Authors:  Jonathan K Alder; Erin M Parry; Srinivasan Yegnasubramanian; Christa L Wagner; Lawrence M Lieblich; Robert Auerbach; Arleen D Auerbach; Sarah J Wheelan; Mary Armanios
Journal:  Hum Mutat       Date:  2013-09-11       Impact factor: 4.878

9.  Association of Donor and Recipient Telomere Length with Clinical Outcomes following Lung Transplantation.

Authors:  Andrew M Courtwright; Sabrina Fried; Julian A Villalba; Anna Moniodis; Indira Guleria; Isabelle Wood; Edgar Milford; Hari H Mallidi; Gary M Hunninghake; Benjamin A Raby; Suneet Agarwal; Philip C Camp; Ivan O Rosas; Hilary J Goldberg; Souheil El-Chemaly
Journal:  PLoS One       Date:  2016-09-02       Impact factor: 3.240

10.  Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.

Authors:  Ganesh Raghu; Martine Remy-Jardin; Jeffrey L Myers; Luca Richeldi; Christopher J Ryerson; David J Lederer; Juergen Behr; Vincent Cottin; Sonye K Danoff; Ferran Morell; Kevin R Flaherty; Athol Wells; Fernando J Martinez; Arata Azuma; Thomas J Bice; Demosthenes Bouros; Kevin K Brown; Harold R Collard; Abhijit Duggal; Liam Galvin; Yoshikazu Inoue; R Gisli Jenkins; Takeshi Johkoh; Ella A Kazerooni; Masanori Kitaichi; Shandra L Knight; George Mansour; Andrew G Nicholson; Sudhakar N J Pipavath; Ivette Buendía-Roldán; Moisés Selman; William D Travis; Simon Walsh; Kevin C Wilson
Journal:  Am J Respir Crit Care Med       Date:  2018-09-01       Impact factor: 21.405

View more
  1 in total

Review 1.  Telomere-mediated lung disease.

Authors:  Jonathan K Alder; Mary Armanios
Journal:  Physiol Rev       Date:  2022-05-09       Impact factor: 46.500

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.